Research Article

Identification of a Novel Metastasis-Related miRNAs-Based Signature for Predicting the Prognosis of Hepatocellular Carcinoma

Table 1

Clinicopathological characteristics of training cohort and validation cohort.

OverallTraining cohortValidation cohort

n344172172
Age (mean (SD))59.35 (13.19)60.21 (13.30)58.50 (13.07)0.23
Gender = male (%)236 (68.6)118 (68.6)118 (68.6)1

Pathology grade (%)0.406
 G153 (15.4)25 (14.5)28 (16.3)
 G2160 (46.5)83 (48.3)77 (44.8)
 G3114 (33.1)52 (30.2)62 (36.0)
 G413 (3.8)9 (5.2)4 (2.3)
 Unknown4 (1.2)3 (1.7)1 (0.6)

Clinical stage (%)0.575
 Stage I162 (47.1)74 (43.0)88 (51.2)
 Stage II77 (22.4)42 (24.4)35 (20.3)
 Stage III3 (0.9)2 (1.2)1 (0.6)
 Stage IIIA59 (17.2)30 (17.4)29 (16.9)
 Stage IIIB9 (2.6)4 (2.3)5 (2.9)
 Stage IIIC9 (2.6)4 (2.3)5 (2.9)
 Stage IV1 (0.3)0 (0.0)1 (0.6)
 Stage IVB2 (0.6)2 (1.2)0 (0.0)
 Unknown22 (6.4)14 (8.1)8 (4.7)

T classification (%)0.711
 T1169 (49.1)80 (46.5)89 (51.7)
 T282 (23.8)45 (26.2)37 (21.5)
 T2a1 (0.3)0 (0.0)1 (0.6)
 T2b1 (0.3)0 (0.0)1 (0.6)
 T342 (12.2)23 (13.4)19 (11.0)
 T3a26 (7.6)12 (7.0)14 (8.1)
 T3b7 (2.0)2 (1.2)5 (2.9)
 T413 (3.8)8 (4.7)5 (2.9)
 TX1 (0.3)1 (0.6)0 (0.0)
 Unknown2 (0.6)1 (0.6)1 (0.6)

M classification (%)0.455
 M0248 (72.1)119 (69.2)129 (75.0)
 M13 (0.9)2 (1.2)1 (0.6)
 MX93 (27.0)51 (29.7)42 (24.4)

N classification (%)0.407
 N0241 (70.1)115 (66.9)126 (73.3)
 N13 (0.9)1 (0.6)2 (1.2)
 NX99 (28.8)55 (32.0)44 (25.6)
 Unknown1 (0.3)1 (0.6)0 (0.0)